ENT Medical News

Become a Member Today!
Register

Most Viewed Abstracts

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Wirth LJ et al. – Panitumumab, carboplatin, paclitaxel and IMRT are well tolerated and appear highly active in the treatment of SCCHN.

Methods

Phase I dose-finding study investigated escalating doses of paclitaxel (Taxol) given concurrently with panitumumab, carboplatin and intensity-modulated radiotherapy (IMRT) for stage III–IVB SCCHN
Untreated patients with oral cavity, oropharynx, larynx, hypopharynx or unknown primaries eligible
Additional eligibility criteria included measurable disease, good performance status and no contraindication to therapy
Patients received weekly fixed doses of panitumumab and carboplatin plus escalating doses of paclitaxel with IMRT

Results

19 patients enrolled on to 2 dose levels (DLs): weekly paclitaxel 15 mg/m2 (n = 3) and 30 mg/m2
1 dose-limiting toxicity occurred in DL 2, which was declared maximum tolerated dose
All patients experienced mucositis, primarily grade 3 or more
Oral pain, xerostomia, dysphagia, weight loss, dermatitis, nausea and acneiform rash were frequent
All patients had partial response according to RECIST, whereas overall complete clinical response rate was 95%
Median follow-up of 21 months, 18 of 19 patients (95%) remained disease free